Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole versus cetrorelix acetate for prevention of ovarian hyperstimulation syndrome after IVF
IRCT20240627062268N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, single-blind trial of letrozole and cetrorelix in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Ovarian hyperstimulation syndrome. Started Sep 2024; status: completed.
02
Drugs
letrozolecetrorelix
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on IRCT20240627062268N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240627062268N1.